Invivyd (NASDAQ: IVVD) announces FDA IND clearance for VYD2311 pivotal program

Rhea-AI Filing Summary

Invivyd, Inc. filed a current report to highlight a key regulatory milestone for its COVID-19 program. On October 6, 2025, the company issued a press release announcing U.S. IND clearance and alignment with the U.S. FDA on a pivotal clinical program for VYD2311, described as a vaccine-alternative antibody to prevent COVID. The press release was furnished as Exhibit 99.1 to this report.

Insights

Biotech regulatory and clinical strategy analyst

FDA IND clearance and pivotal-program alignment mark a major step for VYD2311.

Invivyd reports U.S. IND clearance and alignment with the U.S. FDA on a pivotal clinical program for VYD2311, a vaccine-alternative antibody to prevent COVID. IND clearance typically allows clinical trials to proceed under FDA oversight.

Alignment with the FDA on a pivotal program suggests the agency and company have a shared view of the trial design needed to support a potential future marketing application. This can reduce regulatory uncertainty around endpoints, patient population, and overall development path.

If the pivotal program advances as planned, future updates on enrollment progress, interim data, or regulatory interactions for VYD2311 would be important to follow in subsequent company communications and periodic reports.

0001832038false00018320382025-10-062025-10-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 6, 2025

Invivyd, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40703		85-1403134
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

209 Church Street New Haven, CT		06510
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 819-0080

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		IVVD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 6, 2025, Invivyd, Inc. issued a press release entitled “Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID.” A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Item 9.01   Financial Statements and Exhibits.  

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated October 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INVIVYD, INC.
Date: October 6, 2025		By:	/s/ Jill Andersen
			Jill Andersen
			Chief Legal Officer and Corporate Secretary

FAQ

What did Invivyd (IVVD) report in its October 6, 2025 8-K?

Invivyd reported that it issued a press release announcing U.S. IND clearance and alignment with the U.S. FDA on a pivotal clinical program for VYD2311, a vaccine-alternative antibody to prevent COVID. The press release is included as Exhibit 99.1.

What is VYD2311 in Invivyd’s latest SEC filing for IVVD?

VYD2311 is described as a vaccine-alternative antibody to prevent COVID. Invivyd’s 8-K states that the company received U.S. IND clearance and FDA alignment on a pivotal clinical program for this antibody, signaling a planned late-stage clinical development path.

What regulatory milestone did Invivyd (IVVD) achieve for VYD2311?

Invivyd announced U.S. IND clearance and alignment with the U.S. FDA on a pivotal clinical program for VYD2311. IND clearance generally permits clinical trials to proceed under FDA oversight, and alignment on a pivotal program frames the development plan for potential future approval discussions.

How did Invivyd disclose the VYD2311 IND clearance to investors?

Invivyd disclosed the milestone in an 8-K under “Other Events,” stating it issued a press release titled “Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311.” The company attached the press release as Exhibit 99.1.

What exhibit is included in Invivyd’s October 6, 2025 8-K for IVVD?

The filing includes Exhibit 99.1, a press release dated October 6, 2025 describing U.S. IND clearance and FDA alignment on a pivotal clinical program for VYD2311. It also lists Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.